Xueji Biotechnology

Executive Summary

Xueji Biotechnology is a preclinical-stage Chinese stem cell company pioneering iPSC-derived platelet therapies for thrombocytopenia. Founded in 2021 and based in Suzhou, the company leverages directed differentiation of induced pluripotent stem cells to produce functional platelets, addressing critical needs in oncology, liver disease, and critical care. With $200M in estimated total funding, Xueji is advancing its lead program toward IND-enabling studies, positioning itself as a leader in the emerging field of off-the-shelf platelet replacement. The company's platform also enables drug development for platelet-related disorders, broadening its potential impact. Given the high unmet need for safe, scalable platelet products, Xueji's technology could transform transfusion medicine and reduce dependence on donor-derived platelets. However, the technology remains unvalidated in humans, and manufacturing challenges for iPSC-derived blood products are significant. The company's progress over the next 12–18 months will be critical, with key milestones including IND filing, preclinical efficacy data, and potential strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead iPSC-Platelet Candidate40% success
• H2 2026Partnership with Major Pharma for Co-Development50% success
• Q3 2026Series C Funding Round65% success